2007
Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction
McNamara RL, Herrin J, Wang Y, Curtis JP, Bradley EH, Magid DJ, Rathore SS, Nallamothu BK, Peterson ED, Blaney ME, Frederick P, Krumholz HM. Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction. The American Journal Of Cardiology 2007, 100: 1227-1232. PMID: 17920362, PMCID: PMC2715362, DOI: 10.1016/j.amjcard.2007.05.043.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overArrhythmias, CardiacCaliforniaCohort StudiesEmergency Service, HospitalEmergency TreatmentFemaleFibrinolytic AgentsHospital MortalityHumansMaleMedical RecordsMyocardial InfarctionOutcome Assessment, Health CareRegistriesRetrospective StudiesThrombolytic TherapyTime and Motion StudiesTime FactorsConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionNeedle timeFibrinolytic therapyMyocardial infarctionHospital mortalitySymptom onsetOdds ratioReperfusion strategyAdjunctive medicationsHospital arrivalShorter doorTimely administrationNational registryRepresentative cohortPatientsMortalityInfarctionTherapyIndependent effectsCohortMinutesSmaller centersOnsetImpact of delay
2006
Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter
Segal J, McNamara R, Miller M, Powe N, Goodman S, Robinson K, Bass E. Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter. 2006, 2010: cd001938. PMID: 17636690, PMCID: PMC10759270, DOI: 10.1002/14651858.cd001938.pub2.Peer-Reviewed Original ResearchConceptsAggregate odds ratioRisk of hemorrhageAtrial fibrillationStroke preventionMajor hemorrhageOdds ratioDose warfarinMajor bleedsModerate evidenceCochrane Collaboration's CENTRAL databaseNon-postoperative atrial fibrillationNon-rheumatic atrial fibrillationLow molecular weight heparinAdditional major bleedsLow-dose warfarinMore major bleedingMore major bleedsMore major hemorrhageRCTs of patientsPrimary stroke preventionLow-risk patientsRheumatic valvular diseasePrevention of thromboembolismRisk of strokeTrials of drugs
2001
Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter
Segal J, McNamara R, Miller M, Powe N, Goodman S, Robinson K, Bass E. Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter. Cochrane Database Of Systematic Reviews 2001, cd001938. PMID: 11279741, DOI: 10.1002/14651858.cd001938.Peer-Reviewed Original ResearchConceptsRisk of hemorrhageAtrial fibrillationStroke preventionMajor hemorrhageDose warfarinMajor bleedsOdds ratioModerate evidenceCochrane Collaboration's CENTRAL databaseNon-postoperative atrial fibrillationNon-rheumatic atrial fibrillationLow molecular weight heparinAdditional major bleedsAggregate odds ratioLow-dose warfarinMore major bleedingMore major bleedsMore major hemorrhageRCTs of patientsPrimary stroke preventionLow-risk patientsRheumatic valvular diseasePrevention of thromboembolismRisk of strokeTrials of drugs
2000
Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials.
Miller M, McNamara R, Segal J, Kim N, Robinson K, Goodman S, Powe N, Bass E. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. The Journal Of Family Practice 2000, 49: 1033-46. PMID: 11093570.Peer-Reviewed Original ResearchConceptsAF conversionAtrial fibrillationSinus rhythmOdds ratioModerate evidenceMultiple antiarrhythmic agentsAdverse event ratesClinical trials databasesEfficacy of agentsAdverse event dataPharmacologic conversionAdverse eventsRandomized trialsTrials databasesCochrane CollaborationAntiarrhythmic agentsClinical trialsStudy qualityAgent efficacySuggestive evidenceEvent ratesFlecainideDisopyramideRelative efficacyStrong evidence